Definitive Contract HHSN261201200092C

<p>This is a $224,363 firm-fixed-price federal contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. government, to LP Therapeutics, Inc., a small business. The contract is for the development of nanoparticles to eradicate leukemia stem cells. The award has a completion date of July 31, 2015. This contract appears to be a standalone award, not associated with a larger contract vehicle.</p>

This is a $200,000.00 Small Business Innovation Research (SBIR) Program Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Nanomaterial Innovation LTD, a woman-owned limited liability company. The contract is for the development of &quot;MULTIFUNCTIONAL SIRNA NANOPARTICLES FOR AML THERAPY&quot;, which aligns with NCI's research focus on cancer therapeutics. The contract has a firm fixed price pricing type and was awarded on September 24, 2010 with a...

<p>This is a $299,813 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Hylapharm LLC, a self-certified small disadvantaged business, under the SBIR Program Phase I. The contract is for the development of &quot;Targeted Nanoparticle Treatment for Breast Cancer Stem Cells.&quot; This contract has a Total Small Business set-aside designation. The contract has an ultimate completion date of September 17, 2016.</p>

<p>This is a cost-plus-fixed-fee SBIR Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to LP Therapeutics, Inc. for the development of novel therapeutic agents targeting cancer stem cells. The contract has a total ceiling value of $1,489,000.12 and a period of performance ending on March 18, 2019. The contract was set aside for small businesses. No information is provided about major subcontractors.</p>

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to Lumicell Inc. The contract, valued at $248,461.00, is for the development of novel imaging agents to expand the clinical toolkit for cancer diagnosis, staging, and treatment. The contract has a firm fixed-price pricing type and a period of performance through December 5, 2013. Lumicell Inc. is a for-profit...

This is a $182,050 firm fixed price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanoivd, Inc., a small disadvantaged, woman-owned business. The contract is for TAS::75 0849::TAS and has a total small business set-aside designation. The period of performance runs from the award date of September 30, 2010 through the ultimate completion date of March 30, 2011. Nanoivd, Inc. is the prime contractor, and no subcontractors are mentioned. The contract...

This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...

<p>This is a $149,499.00 firm fixed-price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to L-Nutra, Inc., a for-profit small business organization. The contract is for &quot;Medicinal Food for the Protection of Patients and Sensitization of Cancer Cells to Chemotherapy.&quot; It has a period of performance ending on April 7, 2011. The contract was awarded on September 30, 2010 and is set aside for small businesses.</p>

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanotarget LLC for the development of a nanoparticle CD8 T cell regimen for cancer therapy. The firm-fixed-price contract has a ceiling value of $174,251 and a period of performance ending on May 31, 2010. No subcontractors are mentioned. The SBIR program supports research and development of innovative technologies by small businesses to address key...

<p>This is a $1,908,932.02 Firm Fixed Price Definitive Contract awarded by the National Institutes of Health (NIH) National Cancer Institute to Photolitec LLC, a small business limited liability company, for SBIR Phase II research on image-guided photodynamic therapy in combination with chemotherapy for lung cancer treatment. The contract was set aside for Total Small Business and has a completion date of February 18, 2022.</p>